GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Biocept Inc (OTCPK:BIOCQ) » Definitions » EBITDA per Share
中文

Biocept (Biocept) EBITDA per Share : $-47.62 (TTM As of Jun. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Biocept EBITDA per Share?

Biocept's EBITDA per Share for the three months ended in Jun. 2023 was $-3.10. Its EBITDA per Share for the trailing twelve months (TTM) ended in Jun. 2023 was $-47.62.

During the past 3 years, the average EBITDA per Share Growth Rate was 46.50% per year. During the past 5 years, the average EBITDA per Share Growth Rate was 74.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per Share growth rate using EBITDA per Share data.

The historical rank and industry rank for Biocept's EBITDA per Share or its related term are showing as below:

BIOCQ' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 45.6   Med: 64.45   Max: 91.2
Current: 46.5

During the past 12 years, the highest 3-Year average EBITDA per Share Growth Rate of Biocept was 91.20% per year. The lowest was 45.60% per year. And the median was 64.45% per year.

BIOCQ's 3-Year EBITDA Growth Rate is ranked better than
87.43% of 183 companies
in the Medical Diagnostics & Research industry
Industry Median: 3 vs BIOCQ: 46.50

Biocept's EBITDA for the three months ended in Jun. 2023 was $-3.21 Mil.

During the past 3 years, the average EBITDA Growth Rate was -7.80% per year. During the past 5 years, the average EBITDA Growth Rate was 21.10% per year. During the past 10 years, the average EBITDA Growth Rate was 1.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

During the past 12 years, the highest 3-Year average EBITDA Growth Rate of Biocept was 66.50% per year. The lowest was -32.10% per year. And the median was -10.90% per year.


Biocept EBITDA per Share Historical Data

The historical data trend for Biocept's EBITDA per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biocept EBITDA per Share Chart

Biocept Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EBITDA per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2,606.44 -349.49 -41.95 -1.78 -53.52

Biocept Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
EBITDA per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -17.53 -17.05 -16.43 -11.05 -3.10

Biocept EBITDA per Share Calculation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Biocept's EBITDA per Share for the fiscal year that ended in Dec. 2022 is calculated as

EBITDA per Share(A: Dec. 2022 )
=EBITDA/Shares Outstanding (Diluted Average)
=-30.241/0.565
=-53.52

Biocept's EBITDA per Share for the quarter that ended in Jun. 2023 is calculated as

EBITDA per Share(Q: Jun. 2023 )
=EBITDA/Shares Outstanding (Diluted Average)
=-3.211/1.037
=-3.10

EBITDA per Share for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-47.62

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biocept  (OTCPK:BIOCQ) EBITDA per Share Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals EBIT. EBIT is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost, it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies.


Biocept EBITDA per Share Related Terms

Thank you for viewing the detailed overview of Biocept's EBITDA per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Biocept (Biocept) Business Description

Traded in Other Exchanges
N/A
Address
9955 Mesa Rim Road, San Diego, CA, USA, 92121
Biocept Inc develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information for treating and monitoring patients diagnosed with a variety of cancers. In addition to its portfolio of blood-based liquid biopsy assays, Biocept has developed the CNSide cerebrospinal fluid assay that detects cancer that has metastasized to the central nervous system. Biocept's patented Target Selector technology captures and quantitatively analyzes CSF tumor cells for tumor-associated molecular markers, using technology first developed for use in blood. It is also leveraging its molecular diagnostic capabilities to offer nationwide COVID-19 RT-PCR testing to support public health efforts during this unprecedented pandemic.
Executives
Robert Walsh officer: VP, Controller 9955 MESA RIM ROAD, SAN DIEGO CA 92121
Quyen Thi Dao-haddock director C/O: PRESIDIO PROPERTY TRUST, INC., 1282 PACIFIC OAKS PLACE, ESCONDIDO CA 92029
Philippe Marchand officer: Chief Operations Officer C/O BIOCEPT, INC., 9955 MESA RIM ROAD, SAN DIEGO CA 92121
Darrell Taylor officer: Sr. V.P., General Counsel C/O BIOCEPT, INC., 9955 MESA RIM ROAD, SAN DIEGO CA 92121
David F Hale director, officer: EXECUTIVE CHAIRMAN 1042-B NORTH EL CAMINO REAL, SUITE 430, ENCINITAS CA 92024
Antonino Morales director C/O BICOCEPT, INC., 9955 MESA RIM ROAD, SAN DIEGO CA 92121
Linda M Rubinstein director 25861 INDUSTRIAL BLVD, HAYWARD CA 94545
Samuel D Riccitelli director 2850 FRONTIER DR., WARSAW IN 46582
Michael C Dugan officer: Chief Med Off & Med. Director 2211 MICHIGAN AVE, SANTA MONICA CA 90404-3900
Dunn Cory officer: Sr. VP Corp. Development C/O BIOCEPT, INC., 5810 NANCY RIDGE DR., # 150, SAN DIEGO CA 92121
Edwin Hendrick officer: SVP, Chief Commercial Officer 2010 MAIN STREET, SUITE 600, IRVINE CA 92614
Michael J Terry officer: Sr VP Comm. Operations
Marsha Alpert Chandler director 7863 ENTRADA ANGELICA, SAN DIEGO CA 92127
Michael W. Nall director, officer: CEO AND PRESIDENT 4 WOODHAVEN DRIVE, LAGUNA NIGUEL CA 92677
Timothy Kennedy officer: CFO, Sr V.P. Operations & Sec. 5810 NANCY RIDGE DRIVE, SUITE 150, SAN DIEGO CA 92121